Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

313
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
313
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

266
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
266
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

156
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
156
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

191
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
191
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

143
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
143
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

219
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
219

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Device-Pocket Fat Sampling For Amyloid Screening During Cardiac Device Implantation: A Prospective Study.

European journal of heart failure·2026
Same author

Long-RP Tachycardia in a Professional Cyclist: From Smartwatch to Ablation.

JACC. Case reports·2026
Same author

RoMa: A Cardiopulmonary Exercise Testing Based Risk Tool in Hypertrophic Cardiomyopathy.

Journal of the American Heart Association·2026
Same author

MECKI score thresholds for heart transplantation referral of ambulatory heart failure patients.

ESC heart failure·2026
Same author

Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm.

Journal of the American College of Cardiology·2026
Same author

Non-invasive stroke volume assessment during cardiopulmonary exercise testing provides additional insight beyond O<sub>2</sub>-pulse in hypertrophic cardiomyopathy.

Scientific reports·2026
Same journal

Rethinking triglycerides in the management of ASCVD.

European journal of preventive cardiology·2026
Same journal

Mapping the continuum: polygenic risk of coronary artery disease.

European journal of preventive cardiology·2026
Same journal

Why is Transition so Relevant to Prevention in Congenital Heart Disease? Start Early, Educate, Empower Families and Patients.

European journal of preventive cardiology·2026
Same journal

Beyond Awareness and Diagnosis: From Knowledge to Action for Blood Pressure Control in Coronary Artery Disease.

European journal of preventive cardiology·2026
Same journal

Harmonica-based breathing exercises during hybrid cardiac telerehabilitation: a randomized controlled trial (HARMONY CR).

European journal of preventive cardiology·2026
Same journal

First count the particles: ApoB, the LDL-C/TC ratio, and the hierarchy of lipid risk assessment.

European journal of preventive cardiology·2026
See all related articles

Related Experiment Video

Updated: Nov 28, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.4K

Risk stratification in cardiomyopathy.

Gianfranco Sinagra1, Cosimo Carriere1, Francesco Clemenza2

  • 1Cardiothoracovascular Department of Trieste, University of Trieste, Italy.

European Journal of Preventive Cardiology
|November 26, 2020
PubMed
Summary
This summary is machine-generated.

Cardiopulmonary exercise testing (CPET) offers crucial prognostic insights for cardiomyopathies, aiding risk stratification beyond traditional heart failure metrics. Integrating CPET data into scores like the Metabolism Exercise Cardiac Kidney Index enhances patient management and outcomes.

Keywords:
CPETCardiomyopathyMECKY scoreexerciseprognosisrisk stratification

More Related Videos

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

11.2K

Related Experiment Videos

Last Updated: Nov 28, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.4K
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.7K
In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells
09:05

In Vitro Differentiation of Human Mesenchymal Stem Cells into Functional Cardiomyocyte-like Cells

Published on: August 9, 2017

11.2K

Area of Science:

  • Cardiology
  • Exercise Physiology
  • Clinical Risk Stratification

Background:

  • Accurate prognostic stratification is vital for managing cardiomyopathies, primarily focusing on arrhythmic events and heart failure.
  • Traditional risk assessment often overlooks valuable data obtainable through cardiopulmonary exercise testing (CPET).
  • Existing risk scores may not fully capture the prognostic nuances of various cardiomyopathies.

Purpose of the Study:

  • To evaluate the role of cardiopulmonary exercise testing (CPET) in improving prognostic stratification for patients with cardiomyopathies.
  • To explore specific CPET parameters and their correlation with prognosis across different cardiomyopathy types.
  • To advocate for the routine integration of CPET into advanced heart failure center evaluations for comprehensive risk assessment.

Main Methods:

  • Analysis of cardiopulmonary exercise testing (CPET) data, including peak oxygen consumption, ventilation/carbon dioxide production slope, and chronotropic competence.
  • Integration of CPET-derived variables into established risk stratification scores, such as the Metabolism Exercise Cardiac Kidney Index.
  • Review of existing literature on CPET findings in hypertrophic, dilated, arrhythmogenic, and restrictive cardiomyopathies.

Main Results:

  • In hypertrophic cardiomyopathy, reduced peak oxygen consumption, increased ventilation/carbon dioxide production slope, and chronotropic incompetence are linked to poorer prognosis.
  • In dilated cardiomyopathy, the percentage of peak oxygen consumption and the ventilation/carbon dioxide production slope are associated with increased cardiovascular risk.
  • Limited data exist for arrhythmogenic and restrictive cardiomyopathies, highlighting a need for further research.

Conclusions:

  • Cardiopulmonary exercise testing (CPET) provides significant prognostic information for cardiomyopathies, complementing traditional assessments.
  • Specific CPET variables demonstrate utility in risk stratifying patients with hypertrophic and dilated cardiomyopathies.
  • Early and routine referral to specialized centers for comprehensive risk stratification including CPET is recommended for all cardiomyopathy patients.